[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Delcath Systems Inc (DCTH)

Delcath Systems Inc (DCTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 382,158
  • Shares Outstanding, K 34,522
  • Annual Sales, $ 85,230 K
  • Annual Income, $ 2,700 K
  • EBIT $ -2 M
  • EBITDA $ -3 M
  • 60-Month Beta 0.54
  • Price/Sales 4.64
  • Price/Cash Flow 219.23
  • Price/Book 3.50

Options Overview Details

View History
  • Implied Volatility 70.12% (-4.67%)
  • Historical Volatility 41.24%
  • IV Percentile 24%
  • IV Rank 10.16%
  • IV High 289.81% on 02/06/26
  • IV Low 45.27% on 08/21/25
  • Expected Move (DTE 32) 1.76 (15.89%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 1,511
  • Volume Avg (30-Day) 308
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 10,875
  • Open Int (30-Day) 10,309
  • Expected Range 9.31 to 12.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.16
  • Number of Estimates 1
  • High Estimate $-0.16
  • Low Estimate $-0.16
  • Prior Year $0.07
  • Growth Rate Est. (year over year) -328.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.05 +10.15%
on 04/29/26
12.27 -9.78%
on 05/07/26
+0.08 (+0.73%)
since 04/15/26
3-Month
8.48 +30.47%
on 02/27/26
12.27 -9.78%
on 05/07/26
+1.76 (+18.90%)
since 02/13/26
52-Week
8.12 +36.33%
on 11/20/25
18.23 -39.28%
on 05/20/25
-4.98 (-31.03%)
since 05/15/25

Most Recent Stories

More News
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the...

DCTH : 11.07 (-3.40%)
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C....

DCTH : 11.07 (-3.40%)
Delcath Systems Q1 Earnings Call Highlights

Delcath Systems (NASDAQ:DCTH) reported first-quarter 2026 revenue growth and reiterated its full-year outlook, while updating expectations for U.S. treatment-center activations and outlining progress across...

DCTH : 11.07 (-3.40%)
Delcath Systems Reports First Quarter 2026 Results and Business Highlights

2026 Revenue Guidance of at least $100M Conference Call Today at 8:30 a.m. Eastern Time

DCTH : 11.07 (-3.40%)
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective analysis...

DCTH : 11.07 (-3.40%)
Delcath Systems: Can Profitability Survive the Transition from Trial Data to Commercial Execution?

Barchart Research What to Expect from DCTH Earnings DCTH Generated May 6, 2026 Current Price $11.26 EPS Estimate $$-0.01 Consensus Rating Strong Buy Average Move 9.66% Delcath Systems: Can Profitability...

DCTH : 11.07 (-3.40%)
Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7,...

DCTH : 11.07 (-3.40%)
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT ® Hepatic Delivery System...

DCTH : 11.07 (-3.40%)
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will attend the Society of Interventional Radiology (SIR)...

DCTH : 11.07 (-3.40%)
Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Publication Highlights Promise of Combined Percutaneous Hepatic Perfusion and Immunotherapy in Metastatic Uveal Melanoma

DCTH : 11.07 (-3.40%)

Business Summary

Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.

See More

Key Turning Points

3rd Resistance Point 11.75
2nd Resistance Point 11.54
1st Resistance Point 11.30
Last Price 11.07
1st Support Level 10.85
2nd Support Level 10.64
3rd Support Level 10.40

See More

52-Week High 18.23
Fibonacci 61.8% 14.37
Fibonacci 50% 13.17
Fibonacci 38.2% 11.98
Last Price 11.07
52-Week Low 8.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.